Società | Nome | Borsa | Settore | Industria | Capitalizzazione di mercato | Rapporto Prezzo/Utile | Rapporto PEG | Ultimo prezzo di scambio | Variazione giornaliera (%) | Fair Value | Rialzo Fair Value | Etichetta Fair Value | Price Target (analisti) | Rialzo target analisti | Salute complessiva |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
AddLife | Stoccolma | Salute | Ricerca medica e biotecnologica | 16,52 Mrd SEK | 141,1x | -2,39 | 135,10 SEK | -1,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 20,7% Rialzo | Fai l’upgrade a Pro+ | |
BioArctic | Stoccolma | Salute | Ricerca medica e biotecnologica | 13,87 Mrd SEK | -157,2x | 1,2 | 157,80 SEK | 2,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Bioinvent | Stoccolma | Salute | Ricerca medica e biotecnologica | 2,92 Mrd SEK | -7,6x | 0,31 | 43,75 SEK | 0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Hansa Biopharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 2,61 Mrd SEK | -3,5x | -0,12 | 38,74 SEK | -2,2% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Devyser Diagnostics AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 2,11 Mrd SEK | -32,4x | -3,65 | 127,50 SEK | -0,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 20,1% Rialzo | Fai l’upgrade a Pro+ | |
Vicore Pharma Holding AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,96 Mrd SEK | -4,6x | -0,21 | 8,27 SEK | -1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
XSpray Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,92 Mrd SEK | -8,4x | -0,89 | 57,60 SEK | -3,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 27,1% Rialzo | Fai l’upgrade a Pro+ | |
Nykode Therapeutics | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,70 Mrd SEK | -4,5x | 13,98 SEK | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Cereno Scientific | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,54 Mrd SEK | -19,8x | 0,24 | 5,54 SEK | -0,1% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Egetis Therapeutics AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,51 Mrd SEK | -3,9x | -0,61 | 4,56 SEK | -0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Nanoform Finland Plc | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,48 Mrd SEK | -6,7x | -9,53 | 17,28 SEK | 0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Diamyd Medical | Stoccolma | Salute | Ricerca medica e biotecnologica | 1,36 Mrd SEK | -8,1x | 1,09 | 12,94 SEK | -0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Promimic AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 688,46 Mln SEK | -61,8x | -4,57 | 37,40 SEK | 1,4% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Hamlet Pharma AB | Spotlight | Salute | Ricerca medica e biotecnologica | 671,05 Mln SEK | -16,1x | 0,45 | 4 SEK | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Intellego Technologies AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 658 Mln SEK | 7,3x | 0,05 | 24 SEK | 1,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Cantargia AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 547,39 Mln SEK | -2,3x | -0,08 | 3 SEK | 1,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Alligator Bioscience | Stoccolma | Salute | Ricerca medica e biotecnologica | 529,11 Mln SEK | -2x | -0,07 | 0,70 SEK | -17,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Mendus AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 479,12 Mln SEK | -2,8x | -0,04 | 9,54 SEK | -6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 37,9% Rialzo | Fai l’upgrade a Pro+ | |
Saniona AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 470,54 Mln SEK | -4,6x | 0,08 | 4,30 SEK | 0,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | 40,8% Rialzo | Fai l’upgrade a Pro+ | |
Oncopeptides | Stoccolma | Salute | Ricerca medica e biotecnologica | 459,42 Mln SEK | -1,8x | -0,03 | 2,16 SEK | 3,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Initiator Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 411,97 Mln SEK | -21,3x | -0,36 | 7,35 SEK | 3,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
SynAct Pharma AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 367,75 Mln SEK | -1,8x | -0,44 | 8,96 SEK | 0,6% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Curasight AS | Spotlight | Salute | Ricerca medica e biotecnologica | 364,58 Mln SEK | -7x | 0,24 | 17,11 SEK | -3% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Peptonic Medical | Spotlight | Salute | Ricerca medica e biotecnologica | 345,33 Mln SEK | -0,2x | -0,02 | 0,006 SEK | 0% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Medivir | Stoccolma | Salute | Ricerca medica e biotecnologica | 327,53 Mln SEK | -0,2 | 2,93 SEK | 5,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Alzinova | Stoccolma | Salute | Ricerca medica e biotecnologica | 324,56 Mln SEK | -8,9x | -1,57 | 3,64 SEK | -0,5% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Xbrane Biopharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 321,19 Mln SEK | -0,3x | -0,01 | 0,21 SEK | 2,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Guard Therapeutics | Stoccolma | Salute | Ricerca medica e biotecnologica | 277,86 Mln SEK | -3x | -0,07 | 22,60 SEK | 0,9% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | ||
Annexin Pharma | Stoccolma | Salute | Ricerca medica e biotecnologica | 276,08 Mln SEK | -3,5x | 0,52 SEK | 9,7% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | |||
Abliva AB | Stoccolma | Salute | Ricerca medica e biotecnologica | 257,90 Mln SEK | -1,7x | 0,23 | 0,16 SEK | 2,8% | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ | Fai l’upgrade a Pro+ |